tetano
Editor, Senior Moderator
BMC Infect Dis
. 2022 Dec 8;22(1):917.
doi: 10.1186/s12879-022-07890-6.
Ivermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial
Carmen de la Rocha[SUP] 1 2 [/SUP], Marco A Cid-López[SUP] 1 [/SUP], Blanca I Venegas-López[SUP] 1 [/SUP], Sandra C Gómez-Méndez[SUP] 1 [/SUP], Adriana Sánchez-Ortiz[SUP] 1 [/SUP], Alma M Pérez-Ríos[SUP] 3 [/SUP], Ricardo A Llamas-Velázquez[SUP] 4 [/SUP], Aidé I Meza-Acuña[SUP] 3 [/SUP], Bárbara Vargas-Íñiguez[SUP] 1 [/SUP], Daniela Rosales-Galván[SUP] 1 [/SUP], Alejandra Tavares-Váldez[SUP] 1 [/SUP], Nizdali Luna-Gudiño[SUP] 1 [/SUP], Cinthia V Hernández-Puente[SUP] 1 [/SUP], Jovana Milenkovic[SUP] 1 [/SUP], Cecilia Iglesias-Palomares[SUP] 1 [/SUP], Miriam Méndez-Del Villar[SUP] 5 [/SUP], Gerardo A Gutiérrez-Dieck[SUP] 1 [/SUP], Carlos G Valderrábano-Roldán[SUP] 1 [/SUP], Jennefer Mercado-Cerda[SUP] 1 [/SUP], Jocelyn G Robles-Bojórquez[SUP] 1 [/SUP], Arieh R Mercado-Sesma[SUP] 6 7 [/SUP]
Affiliations
Abstract
Background: Despite the development and application of vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) around the world, the scientific community is still trying to find some therapies to avoid or ameliorate the fatal evolution of the Coronavirus disease 2019 (COVID-19). Since the publication of the potential use of ivermectin as a treatment against the disease, a pleiad of information about it has been published. However, the evidence is not strong or weak enough to conclude its usefulness in the clinical evolution of patients infected with SARS-CoV-2. We evaluate the efficacy and safety of ivermectin in the treatment of Mexican patients with asymptomatic and mild COVID-19 in a three-day administration in comparison to placebo.
Methods: A randomized, double-blind, placebo-controlled trial was carried out in 66 adults with asymptomatic and mild COVID-19. Patients were randomly assigned 1:1 ratio to ivermectin plus acetaminophen or placebo plus acetaminophen. The primary endpoint was the proportion of subjects without a disease progression to severity according to COVID-19 guidelines by the National Institutes of Health (NIH) since randomization to 14 days.
Results: None of the participants presented progression to a severe state in either group. Viral load was measured on Days 1, 5, and 14. No significant differences were observed in baseline or 14-day between groups (p = 0.720 and 0.362, respectively). However, on Day 5, a significant difference in viral load was observed between groups (p = 0.039). The frequency of symptoms was similar between groups, and no significant differences were observed. The most frequent symptom was cough. One severe adverse event associated with SARS-CoV-2 infection was observed in the ivermectin group.
Conclusions: At standard doses, ivermectin is not effective to prevent progression to a severe state or reducing symptoms in adults with asymptomatic and mild COVID-19. Trial registration The study was registered with ClinicalTrial.gov (NCT04407507) on May 29, 2020.
Keywords: COVID-19; COVID-19 Treatment; COVID-19 clinical course; Ivermectin; SARS-CoV-2.
. 2022 Dec 8;22(1):917.
doi: 10.1186/s12879-022-07890-6.
Ivermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial
Carmen de la Rocha[SUP] 1 2 [/SUP], Marco A Cid-López[SUP] 1 [/SUP], Blanca I Venegas-López[SUP] 1 [/SUP], Sandra C Gómez-Méndez[SUP] 1 [/SUP], Adriana Sánchez-Ortiz[SUP] 1 [/SUP], Alma M Pérez-Ríos[SUP] 3 [/SUP], Ricardo A Llamas-Velázquez[SUP] 4 [/SUP], Aidé I Meza-Acuña[SUP] 3 [/SUP], Bárbara Vargas-Íñiguez[SUP] 1 [/SUP], Daniela Rosales-Galván[SUP] 1 [/SUP], Alejandra Tavares-Váldez[SUP] 1 [/SUP], Nizdali Luna-Gudiño[SUP] 1 [/SUP], Cinthia V Hernández-Puente[SUP] 1 [/SUP], Jovana Milenkovic[SUP] 1 [/SUP], Cecilia Iglesias-Palomares[SUP] 1 [/SUP], Miriam Méndez-Del Villar[SUP] 5 [/SUP], Gerardo A Gutiérrez-Dieck[SUP] 1 [/SUP], Carlos G Valderrábano-Roldán[SUP] 1 [/SUP], Jennefer Mercado-Cerda[SUP] 1 [/SUP], Jocelyn G Robles-Bojórquez[SUP] 1 [/SUP], Arieh R Mercado-Sesma[SUP] 6 7 [/SUP]
Affiliations
- PMID: 36482326
- DOI: 10.1186/s12879-022-07890-6
Abstract
Background: Despite the development and application of vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) around the world, the scientific community is still trying to find some therapies to avoid or ameliorate the fatal evolution of the Coronavirus disease 2019 (COVID-19). Since the publication of the potential use of ivermectin as a treatment against the disease, a pleiad of information about it has been published. However, the evidence is not strong or weak enough to conclude its usefulness in the clinical evolution of patients infected with SARS-CoV-2. We evaluate the efficacy and safety of ivermectin in the treatment of Mexican patients with asymptomatic and mild COVID-19 in a three-day administration in comparison to placebo.
Methods: A randomized, double-blind, placebo-controlled trial was carried out in 66 adults with asymptomatic and mild COVID-19. Patients were randomly assigned 1:1 ratio to ivermectin plus acetaminophen or placebo plus acetaminophen. The primary endpoint was the proportion of subjects without a disease progression to severity according to COVID-19 guidelines by the National Institutes of Health (NIH) since randomization to 14 days.
Results: None of the participants presented progression to a severe state in either group. Viral load was measured on Days 1, 5, and 14. No significant differences were observed in baseline or 14-day between groups (p = 0.720 and 0.362, respectively). However, on Day 5, a significant difference in viral load was observed between groups (p = 0.039). The frequency of symptoms was similar between groups, and no significant differences were observed. The most frequent symptom was cough. One severe adverse event associated with SARS-CoV-2 infection was observed in the ivermectin group.
Conclusions: At standard doses, ivermectin is not effective to prevent progression to a severe state or reducing symptoms in adults with asymptomatic and mild COVID-19. Trial registration The study was registered with ClinicalTrial.gov (NCT04407507) on May 29, 2020.
Keywords: COVID-19; COVID-19 Treatment; COVID-19 clinical course; Ivermectin; SARS-CoV-2.
Last edited by a moderator: